Tenogenic Potential of Equine Fetal Mesenchymal Stem Cells Under The In Vitro Effect of Bone Morphogenetic Protein-12 (BMP-12).
Authors: Oliva Rene, Núñez Iván, Segunda Moises N, Peralta Oscar A
Journal: Journal of equine veterinary science
Summary
# Editorial Summary Whilst bone morphogenetic protein-12 (BMP-12) has previously been shown to drive tenogenic differentiation in adult equine bone marrow-derived mesenchymal stem cells (BM-MSCs), the capacity of fetal BM-MSCs—which theoretically possess greater plasticity—remained unexplored. Oliva and colleagues cultured equine fetal BM-MSCs under three BMP-12 concentrations (25, 50 and 100 ng/mL) over 21 days, measuring expression of key tenogenic markers including decorin, tenomodulin, scleraxis and collagen 1α1 at both mRNA and protein levels. All three BMP-12 concentrations significantly upregulated tenogenic gene expression, with fetal cells confirming expected MSC immunophenotypes (CD73+, CD34−) and demonstrating robust multipotent capacity. These findings suggest that equine fetal BM-MSCs represent a promising cellular source for regenerative tendon therapies, potentially offering superior differentiation kinetics compared to adult-derived populations—though translation to in vivo efficacy and optimal dosing strategies remain to be established in clinical contexts.
Read the full abstract on PubMed
Practical Takeaways
- •Fetal MSC sources show promise for future regenerative medicine approaches to equine tendon injury, potentially offering superior outcomes compared to adult cell sources.
- •BMP-12 is an effective biological factor for directing MSC differentiation toward tenogenic lineage in vitro, providing a foundation for developing cell-based tendon repair therapies.
- •This research is foundational; clinical applications remain years away and require progression through animal models and safety trials before consideration for therapeutic use in horses.
Key Findings
- •Equine fetal bone marrow-derived MSCs expressed characteristic MSC markers (CD73+, CD34−) and maintained multipotent capacity.
- •BMP-12 exposure at all three concentrations (25, 50, and 100 ng/mL) significantly upregulated mRNA expression of tenogenic markers DCN, TNMD, SCX, and COL1α1 over 21 days.
- •Equine fetal BM-MSCs demonstrated greater tenogenic differentiation potential compared to previously reported adult BM-MSCs when exposed to BMP-12.
- •Protein-level expression of Col1α1 was confirmed alongside gene expression increases, supporting functional tenogenic commitment.